CNS Pharmaceuticals Files S-1 with SEC
Ticker: CNSP · Form: S-1 · Filed: Apr 14, 2025 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | S-1 |
| Filed Date | Apr 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1, pharmaceuticals, ipo-intent
TL;DR
CNS Pharma just filed an S-1, looks like they're gearing up for a stock offering.
AI Summary
CNS Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on April 14, 2025. The company, incorporated in Nevada, is in the pharmaceutical preparations industry and is headquartered in Houston, Texas. This filing indicates a potential offering of securities, though specific details on the offering size or terms are not yet provided in this excerpt.
Why It Matters
This S-1 filing signals CNS Pharmaceuticals' intent to raise capital through a public offering, which could fund its drug development pipeline and future operations.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which carry inherent market and execution risks for early-stage companies.
Key Numbers
- 2834 — SIC Code (Identifies the company's industry as Pharmaceutical Preparations.)
- 12/31 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- John Climaco (person) — Chief Executive Officer
- 20250414 (date) — Filing Date
- 333-286529 (dollar_amount) — SEC File Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on April 14, 2025.
What is CNS Pharmaceuticals, Inc.'s primary business?
CNS Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who is the CEO of CNS Pharmaceuticals, Inc.?
Mr. John Climaco is the Chief Executive Officer of CNS Pharmaceuticals, Inc.
Where is CNS Pharmaceuticals, Inc. headquartered?
CNS Pharmaceuticals, Inc. is headquartered in Houston, Texas, with its principal executive offices located at 2100 West Loop South, Suite 900.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 14, 2025 by John Climaco regarding CNS Pharmaceuticals, Inc. (CNSP).